Active Biotech’s Tasquinimod Shows Promise in Myelofibrosis Treatment

Active Biotech AB ( (SE:ACTI) ) has shared an announcement.

Active Biotech announced positive preclinical data for tasquinimod, a small molecule immunomodulator, in treating myelofibrosis, published in the journal Blood Advances. The study, conducted in collaboration with MD Anderson Cancer Center, showed that tasquinimod reduces disease cell expression and improves survival in advanced myelofibrosis models. These findings support ongoing clinical trials of tasquinimod as both monotherapy and in combination with other drugs, potentially enhancing Active Biotech’s position in the treatment of rare blood cancers.

More about Active Biotech AB

Active Biotech AB is a biotechnology company focused on developing first-in-class immunomodulatory treatments for oncology and immunology indications with high unmet medical needs. The company has a portfolio of projects, including tasquinimod and laquinimod, which are small molecule immunomodulators being developed for hematological malignancies and inflammatory eye disorders, respectively. Active Biotech’s core focus is on tasquinimod’s development for myelofibrosis, a rare blood cancer.

YTD Price Performance: -25.58%

Average Trading Volume: 6,459,221

Technical Sentiment Signal: Strong Sell

Current Market Cap: SEK170.3M

See more data about ACTI stock on TipRanks’ Stock Analysis page.